Css LLC Aurinia Pharmaceuticals Inc. Transaction History

Css LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $47,952 - $89,208	-7,200 Reduced 20.85%	27,338 $206,000
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $192,759 - $431,166	19,180 Added 124.89%	34,538 $428,000
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $708,977 - $1.32 Million	-39,875 Reduced 72.19%	15,358 $351,000
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $274,343 - $591,105	25,100 Added 83.3%	55,233 $1.22 Million
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $14,870 - $21,591	-1,487 Reduced 4.7%	30,133 $391,000
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $162,618 - $247,629	-13,221 Reduced 29.48%	31,620 $411,000
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $10,779 - $13,369	833 Added 1.89%	44,841 $620,000
Q3 2020 Nov 16, 2020	SELL	$13.19 - $16.66 $85,075 - $107,457	-6,450 Reduced 12.78%	44,008 $648,000
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $456,541 - $592,663	32,333 Added 178.39%	50,458 $820,000
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $203,020 - $384,198	17,903 Added 8064.41%	18,125 $263,000
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $861 - $4,755	222 New	222 $4,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.